Arleen López Wilson, Ana Carolina Andrade Biaggi Leite, Nelia Soto-Ruiz, Paula Escalada-Hernández, Cristina García-Vivar
{"title":"Quality of Life of Male Breast Cancer Survivors: A Systematic Review","authors":"Arleen López Wilson, Ana Carolina Andrade Biaggi Leite, Nelia Soto-Ruiz, Paula Escalada-Hernández, Cristina García-Vivar","doi":"10.1155/ecc/6941281","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Introduction:</b> Breast cancer treatments significantly influence the quality of life of cancer survivors. While most studies have focused on female breast cancer survivors, data on the quality of life of men who have undergone medical, surgical or radiological treatments for breast cancer are limited.</p>\n <p><b>Objective:</b> To evaluate the quality of life of male breast cancer survivors.</p>\n <p><b>Methods:</b> A systematic review was conducted according to the PRISMA statement with a search in four databases: PubMed, Embase, Cochrane and Web of Science. We screened and extracted data and assessed the methodological quality of the studies via the Cochrane RoB-2 and ROBINS-I tools for randomised clinical trials and follow-up studies, respectively. The data were presented in a narrative synthesis format.</p>\n <p><b>Results:</b> In total, 993 records were identified, of which three studies were included for analysis: two randomised clinical trials and one cohort study. The interventions in the randomised clinical trials involved evaluating the impact of endocrine therapy and the implementation of online physical training. Although there was a reduction in the overall quality of life during cancer treatment, patients who received tamoxifen monotherapy did not report a clinically significant change in their sexual function. Additionally, moderate exercise was shown to improve physical health and enhance social well-being. In the cohort study, quality of life and symptom burden were evaluated in men with breast cancer treated with endocrine therapies at the time of diagnosis via symptom assessment scales.</p>\n <p><b>Conclusions:</b> Male breast cancer survivors experience a decrease in quality of life during and after treatment. While tamoxifen monotherapy preserves sexual function, moderate-intensity physical rehabilitation significantly improves both quality of life and social functioning. The limited number of studies included in this review highlights the need for further research to address the physical, psychological and social needs of male breast cancer survivors.</p>\n </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/6941281","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Care","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ecc/6941281","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Breast cancer treatments significantly influence the quality of life of cancer survivors. While most studies have focused on female breast cancer survivors, data on the quality of life of men who have undergone medical, surgical or radiological treatments for breast cancer are limited.
Objective: To evaluate the quality of life of male breast cancer survivors.
Methods: A systematic review was conducted according to the PRISMA statement with a search in four databases: PubMed, Embase, Cochrane and Web of Science. We screened and extracted data and assessed the methodological quality of the studies via the Cochrane RoB-2 and ROBINS-I tools for randomised clinical trials and follow-up studies, respectively. The data were presented in a narrative synthesis format.
Results: In total, 993 records were identified, of which three studies were included for analysis: two randomised clinical trials and one cohort study. The interventions in the randomised clinical trials involved evaluating the impact of endocrine therapy and the implementation of online physical training. Although there was a reduction in the overall quality of life during cancer treatment, patients who received tamoxifen monotherapy did not report a clinically significant change in their sexual function. Additionally, moderate exercise was shown to improve physical health and enhance social well-being. In the cohort study, quality of life and symptom burden were evaluated in men with breast cancer treated with endocrine therapies at the time of diagnosis via symptom assessment scales.
Conclusions: Male breast cancer survivors experience a decrease in quality of life during and after treatment. While tamoxifen monotherapy preserves sexual function, moderate-intensity physical rehabilitation significantly improves both quality of life and social functioning. The limited number of studies included in this review highlights the need for further research to address the physical, psychological and social needs of male breast cancer survivors.
乳腺癌治疗显著影响癌症幸存者的生活质量。虽然大多数研究的重点是女性乳腺癌幸存者,但关于接受过乳腺癌医疗、手术或放射治疗的男性生活质量的数据有限。目的:评价男性乳腺癌幸存者的生活质量。方法:根据PRISMA声明,检索PubMed、Embase、Cochrane和Web of Science 4个数据库进行系统评价。我们筛选和提取资料,并分别通过Cochrane rob2和ROBINS-I工具对随机临床试验和随访研究的方法学质量进行评估。这些数据以叙述综合的形式提出。结果:共确定993份记录,其中3项研究纳入分析:2项随机临床试验和1项队列研究。随机临床试验的干预措施包括评估内分泌治疗的影响和在线体育训练的实施。尽管在癌症治疗期间总体生活质量有所下降,但接受他莫昔芬单药治疗的患者并未报告其性功能有临床显著变化。此外,适度的锻炼被证明可以改善身体健康,增强社会幸福感。在队列研究中,通过症状评估量表对诊断时接受内分泌治疗的男性乳腺癌患者的生活质量和症状负担进行评估。结论:男性乳腺癌幸存者在治疗期间和治疗后的生活质量下降。而他莫昔芬单药治疗保留性功能,中等强度的物理康复显着改善生活质量和社会功能。本综述中纳入的研究数量有限,因此需要进一步研究以解决男性乳腺癌幸存者的生理、心理和社会需求。
期刊介绍:
The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of:
- Primary, secondary and tertiary care for cancer patients
- Multidisciplinary and service-user involvement in cancer care
- Rehabilitation, supportive, palliative and end of life care for cancer patients
- Policy, service development and healthcare evaluation in cancer care
- Psychosocial interventions for patients and family members
- International perspectives on cancer care